Developing potent PROTACs tools for selective degradation of HDAC6 protein

References

[1] Batchu SN, Brijmohan AS, Advani A (2016) The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci (Lond) 130:987–1003

[2] Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP (2012) Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem 55:9891–9899

[3] Boettcher M, McManus MT (2015) Choosing the right tool for the job: RNAi, TALEN, or CRISPR. Mol Cell 58:575–585

[4] Davisson MT, Bergstrom DE, Reinholdt LG, Donahue LR (2012) Discovery genetics—the history and future of spontaneous mutation research. Curr Protoc Mouse Biol 2:103–118

[5] El-Brolosy MA, Stainier DYR (2017) Genetic compensation: a phenomenon in search of mechanisms. PLoS Genet 13: e1006780

[6] Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP (2003) The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115:727–738

[7] Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, Van Leeuwen FW, Chanan-Khan AA (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 110:3281–3290

[8] Lai AC, Crews CM (2017) Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov 16:101–114

[9] Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J,Karasawa S, Carmel G, Jackson P,Abbasian M (2012) Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326–2335

[10] Miyake Y, Keusch JJ, Wang L, Saito M, Hess D, Wang X, Melancon BJ, Helquist P, Gut H, Matthias P (2016) Structural insights into HDAC6 tubulin deacetylation and its selective inhibition. Nat Chem Biol 12:748–754

[11] Seto E, Yoshida M (2014) Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol 6: a018713

[12] Sun YH, Zhao XW, Ding N, Gao HY, Wu Y, Yang YQ, Zhao M, Hwang J, Song YG, Liu WL (2018) PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies. Cell Res 28:779–781

[13] Valenzuela-Fernandez A, Cabrero JR, Serrador JM, Sanchez- Madrid F (2008) HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends Cell Biol 18:291–297

[14] Yang K, Song Y, Xie H, Wu H, Wu YT, Leisten ED, Tang W (2018) Development of the first small molecule histone deacetylase 6 (HDAC6) degraders. Bioorg Med Chem Lett 28:2493–2497

[15] Zhou B, Hu JT, Xu F, Chen Z, Bai L, Fernandez-Salas E, Lin M, Liu L, Yang CY, Zhao Y (2018) Discovery of a small-molecule degrader of bromodomain and extra-terminal (BET) proteins with picomolar cellular potencies and capable of achieving tumor regression. J Med Chem 61:462–481

RIGHTS & PERMISSIONS

2019 The Author(s)